# Coding Pitfalls Case Scenarios

## Breast Case Scenario

The summary below is an aide meant to help follow along with the presentation. Participants do **not** need to complete the scenario prior to the session.

History:

A 42 year old female presents with a palpable left breast mass. The axilla area was negative for enlarged lymph nodes.

Imaging:

* Mammogram showed a left breast mass at 10 o’clock measuring 3cm.
* Ultrasound of the left breast: 2 cm mass @10:00 and a left axillary lymph node measuring 1.1 cm

Pathology:

* Biopsy of the breast @10:00: positive for carcinoma NST with tubular carcinoma, NG grade 2, areas of high grade DCIS
  + ER 95% (positive)
  + PR 81-90% (positive)
  + Ki-67 44% (H)
  + HER2 by Immunohistochemistry 2+
  + HER2 by in situ hybridization Positive (amplified)
  + HER2: CEP17 ratio 1.34
  + Average HER2 signals/nucleus 4.75
  + Average CEP17 signals/nucleus 3.55
* Biopsy of left axillary lymph node: Negative for malignancy
* Mastectomy:
  + No residual carcinoma (complete PR)
  + 0/4 SLN, IHC negative

Treatment:

* Neoadjuvant chemotherapy: 6 cycles of TCHP
* Surgery: Bilateral nipple sparing mastectomy, sentinel lymph node biopsy, tissue expander reconstruction.

Discharge Summary:

* Patient had a complete pathologic response to neoadjuvant treatment.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Scenario 1-Breast | | | | | | | | | | | | |
| Primary Site | C50.2 | Clinical Grade | | | | 2 | | Tumor Size Clinical | | | 030 | |
| Histology | 8523 | Pathological Grade | | | | 9 | | Tumor Size Pathological | | | 000 | |
| Behavior | 3 | Post Therapy Grade | | | | 9 | | Tumor Size Summary | | | 030 | |
| MP Rule | M3 |  | | | | | | | | | | |
| H Rule | H4 and then H15 | | | | | | | | | | | |
|  | | | | | | | | | | | | |
| Stage Data items | | | | | | | | | | | | |
| Clinical T | cT2 | Pathological T | | | |  | | Post-therapy T | | | ypT0 | |
| cT Suffix |  | pT Suffix | | | |  | | pT Suffix | | |  | |
| Clinical N | cN0 | Pathological N | | | |  | | Post-therapy N | | | ypN0 | |
| cN Suffix | (f) | pN Suffix | | | |  | | pN Suffix | | | (sn) | |
| Clinical M | cM0 | Pathological M | | | |  | | Post-therapy M | | | cM0 | |
| Clinical Stage | 1B | Pathological Stage | | | |  | | Post-therapy Stage | | | 88 | |
|  | | | | | | | | |
| Summary Stage 2018 | | | | 1-Localized | | | | |
| EOD Primary Tumor | | | | 100 | | | | |
| EOD Regional Nodes | | | | 070 | | | | |
| EOD Mets | | | | 00 | | | | |
| Regional Nodes Positive | | | | 00 | | | | |
| Regional Nodes Examined | | | | 04 | | | | |
| Sentinel Nodes Positive | | | | 00 | | | | |
| Sentinel Nodes Examined | | | | 04 | | | | |
|  | | | | | | | | |
| SSDI’s | | | | | | | | |
| *Positive AxLN Level I-II* | | | | | 00 | | | |
| ER Summary | | | | | 1 | | | |
| ER Percent Positive | | | | | 095 | | | |
| ER Allred Score | | | | | X9 | | | |
| PR Summary | | | | | 1 | | | |
| PR Percent Positive | | | | | R90 | | | |
| PR Allred Score | | | | | X9 | | | |
| HER2 IHC Summary | | | | | 2 | | | |
| HER2 ISH Summary | | | | | 3 | | | |
| HER2 Overall Summary | | | | | 1 | | | |
| HER2 ISH DP Ratio | | | | | 1.3 | | | |
| HER2 ISH DP Copy No | | | | | 4.7 | | | |
| HER2 ISH SP Copy No | | | | | XX.9 | | | |
| Ki-67 (MIB-1) | | | | | 44.0 | | | |
| Oncotype DX Recur Score | | | | | XX9 | | | |
| Oncotype Dx Risk Level Invasive | | | | | 9 | | | |
| Oncotype DX Recur Score - DCIS | | | | | XX6 | | | |
| Oncotype Dx Risk Level – DCIS | | | | | 6 | | | |
| Multigene Signature Method | | | | | 9 | | | |
| Multigene Signature Result | | | | | X9 | | | |
| Response Neoadjuvant Therapy | | | | | 1 | | | |
|  | | | | | | | | |
| Diagnostic Staging Procedure | | | | | 02 | | | |
|  | | | | | | | | |
| Surgery | | | | | | | | |
| Surgical Procedure of Primary Site | | | | | 30 | | | |
| Scope of Regional Lymph Node Surgery | | | | | 2 | | | |
| Surgical Procedure/ Other Site | | | | | 0 | | | |
| Systemic Therapy | | | | | | | | |
| Chemotherapy | | | | | 03 | | | |
| Hormone Therapy | | | | | 88 | | | |
| Immunotherapy | | | | | 01 | | | |
| Hematologic Transplant | | | | | 00 | | | |
| Systemic/ Surgery Sequence | | | | | 7 | | | |
|  | | | | |  | | | |
| Radiation | | | | | | | | | | | |
|  | | | Phase 1 | | | | Phase 2 | | | Phase 3 | |
| Rad Primary Treatment Volume | | | 00 | | | |  | | |  | |
| Rad Treatment Modality | | | 00 | | | |  | | |  | |
| Radiation to Draining Lymph Nodes | | |  | | | |  | | |  | |
| Ext Beam Rad Planning Technique | | |  | | | |  | | |  | |
| Dose per Fraction | | |  | | | |  | | |  | |
| Number of Fractions | | |  | | | |  | | |  | |
| Total Dose | | |  | | | |  | | |  | |
| # of Phases of Rad Tx to this Volume | | | 00 | | | | | | | | |
| Rad Treatment Discontinued Early | | | 00 | | | | | | | | |
| Total Dose | | | 000000 | | | | | | | | |
| Reason no Radiation | | | 1 | | | | | | | | |

## Colon Case Scenario

**History**

Patient had a transverse colectomy for adenocarcinoma of the transverse colon on 4/25/16. The patient presents today for a follow-up barium enema and colonoscopy.

* Labs: 7/25/18 CEA 17 ng/ml (normal < 3 ng/ml)
* Imaging: 7/25/18
  + BE: 2.5 cm polypoid lesion at the anastomotic site shows the typical features of colonic CA
  + CT chest/abd/pel: no evidence of metastasis
* Scopes 7/25/18 Colonoscopy: submucosal tumor located at suture line; biopsies taken
* Treatment 8/24/18 Right hemicolectomy

**Pathology**

7/25/18 Biopsy at anastomosis: Moderately differentiated adenocarcinoma.

8/24/18 Right colon with anastomosis:

* 2.9 cm well differentiated adenocarcinoma with mucinous differentiation at anastomotic site
* Tumor invades muscularis propria;
* LVI: None
* PNI: None
* Proximal, distal, and radial margins free
* 16 lymph nodes negative for metastasis
* A single peritumoral deposit
* MSI low
* KRAS mutated

**Discharge summary**:

Clinicopathological examination showed the lesion was a recurrence of the previous trans-colon cancer, because it was located exactly on the anastomosis and it first showed a feature of submucosal tumor. Plan: FOLFOX

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Scenario 2-Colon | | | | | | | | | | | |
| Primary Site | **C18.9** | Clinical Grade | | | 2 | | Tumor Size Clinical | | | 025 | |
| Histology | 8140 | Pathological Grade | | | 2 | | Tumor Size Pathological | | | 029 | |
| Behavior | 3 | Post Therapy Grade | | |  | | Tumor Size Summary | | | 029 | |
| MP Rule | M7 |  | | | | | | | | | |
| H Rule | H7 | | | | | | | | | | |
|  | | | | | | | | | | | |
| Stage Data items | | | | | | | | | | | |
| Clinical T | cTX | Pathological T | | | pT2 | | Post-therapy T | | |  | |
| cT Suffix |  | pT Suffix | | |  | | pT Suffix | | |  | |
| Clinical N | cN0 | Pathological N | | | pN1c | | Post-therapy N | | |  | |
| cN Suffix |  | pN Suffix | | |  | | pN Suffix | | |  | |
| Clinical M | cM0 | Pathological M | | | cM0 | | Post-therapy M | | |  | |
| Clinical Stage | 99 | Pathological Stage | | | 3A | | Post-therapy Stage | | |  | |
|  | | | | | | | |
| Summary Stage 2018 | | | 3-Regional to Lymph Nodes | | | | |
| EOD Primary Tumor | | | 200 | | | | |
| EOD Regional Nodes | | | 200 | | | | |
| EOD Mets | | | 00 | | | | |
| Regional Nodes Positive | | | 00 | | | | |
| Regional Nodes Examined | | | 16 | | | | |
| Sentinel Nodes Positive | | | 98 | | | | |
| Sentinel Nodes Examined | | | 98 | | | | |
|  | | | | | | | |
| SSDI’s | | | | | | | |
| CEA PreTX Lab Value | | | | 17.0 | | | |
| CEA PreTX Interpretation | | | | 1 | | | |
| Tumor Deposits | | | | 01 | | | |
| Circumferential Resection Margin | | | | XX.1 | | | |
| KRAS | | | | 4 | | | |
| Microsatellite Instability (MSI) | | | | 1 | | | |
|  | | | | | | | |
| Diagnostic Staging Procedure | | | | 02 | | | |
|  | | | | | | | |
| Surgery | | | | | | | |
| Surgical Procedure of Primary Site | | | | 40 | | | |
| Scope of Regional Lymph Node Surgery | | | | 4 | | | |
| Surgical Procedure/ Other Site | | | | 0 | | | |
| Systemic Therapy | | | | | | | |
| Chemotherapy | | | | 88 | | | |
| Hormone Therapy | | | | 00 | | | |
| Immunotherapy | | | | 00 | | | |
| Hematologic Transplant | | | | 00 | | | |
| Systemic/ Surgery Sequence | | | | 0 | | | |
|  | | | |  | | | |
| Radiation | | | | | | | | | | |
|  | | | Phase 1 | | | Phase 2 | | | Phase 3 | |
| Rad Primary Treatment Volume | | | 00 | | |  | | |  | |
| Rad Treatment Modality | | |  | | |  | | |  | |
| Radiation to Draining Lymph Nodes | | |  | | |  | | |  | |
| Ext Beam Rad Planning Technique | | |  | | |  | | |  | |
| Dose per Fraction | | |  | | |  | | |  | |
| Number of Fractions | | |  | | |  | | |  | |
| Total Dose | | |  | | |  | | |  | |
| # of Phases of Rad Tx to this Volume | | | 00 | | | | | | | |
| Rad Treatment Discontinued Early | | | 00 | | | | | | | |
| Total Dose | | | 000000 | | | | | | | |
| Reason no Radiation | | | 1 | | | | | | | |